remoxipride remoxipride remoxipride (roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients). it was initially launched by astrazeneca in 1990 and suspension of its use began in 1993. remoxipride acts as a selective d2 and d3 receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action. remoxiprideclinical datatrade namesroxiamroutes ofadministrationoralatc coden05al04 (who) legal statuslegal status withdrawn pharmacokinetic databioavailability96%protein binding89-98%metabolismhepaticelimination half-life4-7 hoursexcretionrenalidentifiers iupac name 3-bromo-n-methyl]-2,6-dimethoxybenzamide cas number80125-14-0 npubchem cid54477drugbankdb00409 ychemspider49195 yunii0223rd59pekeggd02683 ychemblchembl22242 ycomptox dashboard (epa)dtxsid6045668 chemical and physical dataformulac16h23brn2o3molar mass371.275 g·mol−13d model (jsmol)interactive image smiles ccn2ccc2cnc(=o)c1c(oc)ccc(br)c1oc inchi inchi=1s/c16h23brn2o3/c1-4-19-9-5-6-11(19)10-18-16(20)14-13(21-2)8-7-12(17)15(14)22-3/h7-8,11h,4-6,9-10h2,1-3h3,(h,18,20)/t11-/m0/s1 ykey:gujrsxapgddaba-nshdsacasa-n y ny (what is this?) (verify) due to its short half-life twice daily (bid) dosing is required, although a once-daily controlled-release tablet has been developed. there was some interest in its use in the treatment of treatment-resistant schizophrenia.